Tumor board review

Maybe I should just make my own schedule between the tracks so I have a custom educational day.

Matthijs, I also saw on the schedule that there's a novel format during the educational day and it's a tumor board.

What should I expect from this session?

Yes, thank you for this question, because last time we did a tumor board which focused on the diagnosis and treating brain tumors, including metastasis and meningioma.

This year, it is a combined session together with the supportive care track, and we have a very interesting panel.

with a lot of expertise, and we will focus on symptom management and supportive care.

In this case, it is true that in the field of small cell lung cancer, Can we break through the scope of treatment in the first stage and have more space?

好的,谢谢两位专家,其实我们今天真正的是一个Tumor Board, 有内科的,有外科的,有放疗科医生的参与, 那么其实我们还想用一点点时间浅浅地讨论一下生物标志物的问题, 因为我们其实有了DLL3,塔尔陀单抗,今天又有了B7H3, 那么就想请教范教授,将来小细胞肺癌领域里面是不是要做一些这样的一个标志物, 我们这个治疗选择特别多了 小细胞肺癌距离它的这个精准治疗还有多远了 需不需要做这个生物标志物指导下的治疗 我觉得是特别特别重要的一个话题 也是大家一直在关心的 但我的答案就是还是非常的简单直接 现阶段就是我们觉得

you do these expressions, it may not be very meaningful to our clinical patients, but it is meaningful to our future transformation research.

So I don't think clinical is very supportive.

We actually know for most of the ones, as we were looking back specifically at those, those were on for a longer time, but it's always a discussion.

We have these discussions over and over at Tumor Board about specific patients, how long should we keep them on? I think one gentleman who...

We had a lot of discussions about, I think, kept him on for nine or ten doses.

Part of it is because I felt a little uncomfortable.

And, you know, what I found is that sometimes the you know, following the patient's symptoms are often more telling, you know, patients who've come, you know, they'll have headaches or they have, you know, neurosymptoms, they'll often improve when there's a real response.

And that's often been more reliable sometimes in the imaging.

But I think we've been looking lately at, you know, have we had big recurrences when we kind of a tumor board, everybody thinks, well, we think there's a response here.

We've had We've had some.

For a real patient with colorectal cancer with liver metastases, an honest assessment about the extent of disease, the biology, as we've mentioned many times today, fitness for chemotherapy, ability for curative resections, perioperative chemo and its role, the role of ctDNA.

You know, my question here I think to close out is, you know, how does this actually all come together at your tumor board and what's the best management that you see coming down the pike in say five years or so?

The best management, I think, is going to be once we can perform far more targeted therapies that allow us to spare more normal liver.

I mean, that's really what my, you know, I would say my underlying bias is.